GlassScriptPhysician profile
Brian J Galofaro
NPI 1629298278
$7,705.83
in general payments reported to CMS, 2019-2025
43 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $1,262 · 2021: $1,149 · 2022: $1,280 · 2023: $1,360 · 2024: $552 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $844.01 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $725.45 | 2019-2025 | |
| Pfizer INC. | $579.15 | 2019-2025 | |
| Lilly USA, LLC | $553.43 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $451.40 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $437.76 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $412.37 | 2019-2023 | Breztri |
| Allergan, INC. | $394.53 | 2019-2020 | |
| Amarin Pharma, INC. | $393.20 | 2019-2023 | |
| Amgen INC. | $318.50 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.93 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $205.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $190.02 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $175.28 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pacira Therapeutics, INC. | $161.00 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Galofaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.